PRINTER FRIENDLY
|
In the Spotlight Hooray for Blockbuster Drugs The press is full of stories criticizing the pharmaceutical industry for marketing "blockbuster" drugs that are big on sales but low on innovation. "Pharmaceutical executives, like movie moguls, have focused on creating blockbusters," wrote Melody Petersen in a Los Angeles Times op-ed last January. "They introduce products that they hope will appeal to the masses, and then they promote them like mad. . . . The strategy had a flaw that executives have long ignored: It required extraordinary amounts of promotion at the expense of scientific creativity." Similarly, Marcia Angell, former editor-in-chief of the New England Journal of Medicine, told PBS's Frontline: "The pharmaceutical industry likes to depict itself as a research-based industry, as the source of innovative drugs. Nothing could be further from the truth."
Continue reading . . . News · Peter Orszag versus Paul Ryan: Part Deux, Daily Caller, 7-29-10 Commentary · Another Public Option? How Many Do We Need?, Kathryn Nix, Heritage Foundation, 7-29-10 Research · Do Bad Report Cards Have Consequences? Impacts of Publicly Reported Provider Quality Information on the CABG Market in Pennsylvania, Justin Wang, Jason Hockenberry, Shin-Yi Chou, and Muzhe Yang, National Bureau of Economic Research, July 2010 Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research. For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at phoward@manhattan-institute.org, or via telephone at 212.599.7000. Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at communications@manhattan-institute.org, or via telephone at 212.599.7000. If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line. |
SPOTLIGHT | ||
| Hooray for Blockbuster Drugs | ||
| ||
| ||
| ||
 | ||
| ||
| ||
|
